Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2013

01-10-2013 | Leading Article

β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives

Authors: Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola

Published in: Drugs | Issue 15/2013

Login to get access

Abstract

The common coexistence of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) presents several therapeutic constraints that have not been comprehensively investigated. Pharmacologic modulation of β-adrenoceptor (β-AR) function is one of the critical issues in the treatment of these patients because inhaled β2-AR agonists may induce adverse events in patients with COPD, mainly in those with coexisting CVD. Moreover, the use of β-AR blockers has traditionally been contraindicated in COPD, mainly because of the potential for acute bronchospasm and increased airway hyperresponsiveness after their administration. However, there now appears to be good evidence that β-AR blockers are not only safe but may have benefits in COPD that extend beyond a reduction in cardiovascular mortality. This article starts with a succinct outline of the evolution in our understanding of β-AR modulation in COPD, touching on treatment of COPD with β-AR agonists and the issues of β-AR blockade and cardioselectivity in patients with comorbid CVD. We then summarize the current evidence for a COPD benefit from β-AR blockers and hypothesize on the mode of action. Finally, we provide a view of the future landscape in terms of therapeutic possibilities and what still needs to be resolved, based on our opinion.
Literature
1.
Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106:249–56.PubMedCrossRef
2.
Cockcroft JR, Pedersen ME. β-blockade: benefits beyond blood pressure reduction? J Clin Hypertens (Greenwich). 2012;14:112–20.CrossRef
3.
Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther. 2010;23:1–8.PubMedCrossRef
4.
Cazzola M, Matera MG, Donner CF. Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;65:1595–610.PubMedCrossRef
5.
Cazzola M, Noschese P, D’Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002;121:230–41.PubMedCrossRef
6.
van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest. 2005;127:818–24.PubMedCrossRef
7.
Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.PubMedCrossRef
8.
Cazzola M, Page CP, Rogliani P, Matera MG. β2-Agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690–6.PubMedCrossRef
9.
Billington CK, Hall IP. Novel cAMP signalling paradigms: therapeutic implications for airway disease. Br J Pharmacol. 2012;166:401–10.PubMedCrossRef
10.
Brueckner F, Piscitelli CL, Tsai CJ, Standfuss J, Deupi X, Schertler GF. Structure of β-adrenergic receptors. Methods Enzymol. 2013;520:117–51.PubMedCrossRef
11.
12.
Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med. 2011;17:126–39.PubMedCrossRef
13.
Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science. 1990;248:1547–50.PubMedCrossRef
14.
Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA. 2003;100:1740–4.PubMedCrossRef
15.
Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 2002;298:834–6.PubMedCrossRef
16.
17.
van Gestel AJ, Kohler M, Clarenbach CF. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Discov Med. 2012;14:359–68.PubMed
18.
Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohormonal activation as a link to systemic manifestations of chronic obstructive pulmonary disease. Chest. 2005;128:3618–24.PubMedCrossRef
19.
Volterrani M, Scalvini S, Mazzuero G. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest. 1994;106:1432–7.PubMedCrossRef
20.
Steward RI, Lewis M. Cardiac output during exercise in patients with COPD. Chest. 1986;89:199–205.CrossRef
21.
Patakas D, Louridas G, Kakavelas E. Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease. Thorax. 1982;37:292–5.PubMedCrossRef
22.
Heindl S, Lehnert M, Criée CP. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164:597–601.PubMedCrossRef
23.
Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110:1308–12.PubMedCrossRef
24.
Poirier P, Lacasse Y, Marquis K, Jobin J, LeBlanc P. Post-exercise heart rate recovery and mortality in chronic obstructive pulmonary disease. Respir Med. 2005;99:877–86.PubMedCrossRef
25.
Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, Jensen JS, Jensen GB. Resting heart rate is a predictor of mortality in COPD. Eur Respir J. 2013;42:341–9.PubMedCrossRef
26.
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res. 1986;59:297–309.PubMedCrossRef
27.
Brodde OE. β1- and β2-adrenoceptors in the human heart: properties, function and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203–42.PubMed
28.
Rodefeld MD, Beau SL, Schuessler RB, Boineau JP, Saffitz JE. β-Adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high β2-adrenergic receptor density. J Cardiovasc Electrophysiol. 1996;7:1039–49.PubMedCrossRef
29.
Newton GE, Parker JD. Acute effects of β1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353–8.PubMedCrossRef
30.
Cazzola M, Donner CF, Matera MG. Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax. 1999;54:730–6.PubMedCrossRef
31.
Cazzola M, Matera MG. Should long-acting β2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med. 1999;93:227–9.PubMedCrossRef
32.
Cekici L, Valipour A, Kohansal R, Burghuber OC. Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study. Br J Clin Pharmacol. 2009;67:394–402.PubMedCrossRef
33.
Silke B, Hanratty CG, Riddell JG. Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods. J Cardiovasc Pharmacol. 1999;33:859–67.PubMedCrossRef
34.
Hanratty CG, Silke B, Riddell JG. Evaluation of the effect on heart rate variability of a beta2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods. Br J Clin Pharmacol. 1999;47:157–66.PubMedCrossRef
35.
Newton GE, Azevedo ER, Parker JD. Inotropic and sympathetic responses to the intracoronary infusion of a β2-receptor agonist: a human in vivo study. Circulation. 1999;99:2402–7.PubMedCrossRef
36.
Cazzola M, Calzetta L, Matera MG. β2-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163:4–17.PubMedCrossRef
37.
Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998;114:411–5.PubMedCrossRef
38.
Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2. Reassessment in the larger Quebec cohort. Chest. 2012;142:305–11.PubMedCrossRef
39.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719–25.PubMedCrossRef
40.
Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. β-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002;165:1353–8.PubMedCrossRef
41.
Parker H, Brenya R, Zarich S, Manthous CA. β-agonists for patients with chronic obstructive pulmonary disease and heart disease? Am J Emerg Med. 2008;26:104–5.PubMedCrossRef
42.
Singer AJ, Emerman C, Char DM, Heywood JT, Kirk JD, Hollander JE, Summers R, Lee CC, Wynne J, Kellerman L, Peacock WF. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med. 2008;51:25–34.PubMedCrossRef
43.
Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, Heijdra YF. Bronchodilator responsiveness in patients with chronic heart failure. Heart Lung. 2013;42:208–14.PubMedCrossRef
44.
Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40:135–45.PubMedCrossRef
45.
Coughlin SS, Metayer C, McCarthy EP, Mather FJ, Waldhorn RE, Gersh BJ, DuPraw S, Baughman KL. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol. 1995;142:395–403.PubMed
46.
Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123:1964–9.PubMedCrossRef
47.
Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? Respirology. 2010;15:895–901.PubMedCrossRef
48.
Sengstock DM, Obeidat O, Pasnoori V, Mehra P, Sandberg KR, McCullough PA. Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail. 2002;8:232–8.PubMedCrossRef
49.
Bermingham M, O’Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail. 2011;13:885–91.PubMedCrossRef
50.
Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006;20:571–9.PubMedCrossRef
51.
Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105:571–9.PubMedCrossRef
52.
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25:1341–62.PubMedCrossRef
53.
Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol. 2005;144:317–22.PubMedCrossRef
54.
Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40:193–200.PubMedCrossRef
55.
British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91:v1–52.
56.
57.
Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC, National Heart Lung and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–72.PubMedCrossRef
58.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A. ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;2007(25):1105–87.CrossRef
59.
Cazzola M, Matera MG. β-Blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. Am J Respir Crit Care Med. 2008;178:661–2.PubMedCrossRef
60.
Salpeter S, Ormiston T, Salpeter E. Cardioselective beta blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (19):CD003566.
61.
Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40:2051–65.PubMedCrossRef
62.
Loth DW, Brusselle GG, Lahousse L, Hofman A, Leufkens HG, Stricker BH. Beta-blockers and pulmonary function in the general population: the Rotterdam Study. Br J Clin Pharmacol. 2013. doi:10.​1111/​bcp.​12181.PubMed
63.
Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.PubMedCrossRef
64.
Rutten F, Zuithoff N, Hak E, Grobbee D, Hoes A. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880–7.PubMedCrossRef
65.
Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.PubMedCrossRef
66.
Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013;47:651–6.PubMedCrossRef
67.
Matera MG, Calzetta L, Rinaldi B, Cazzola M. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol. 2012;12:315–22.PubMedCrossRef
68.
Cochrane B, Quinn S, Walters H, Young I. Investigating the adverse respiratory effects of beta-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease. Intern Med J. 2012;42:786–93.PubMedCrossRef
69.
Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63:301–5.PubMedCrossRef
70.
Suissa S, Ernst P. Biases in the observational study of beta blockers in COPD. Thorax. 2008;63:1026–7.PubMed
71.
Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67:977–84.PubMedCrossRef
72.
Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O’Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111:582–7.PubMedCrossRef
73.
Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL, Keteyian SJ, Kitzman DW, Whellan DJ, Ellis SJ, O’Connor CM. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). Am Heart J. 2013;165:193–9.PubMedCrossRef
74.
Rutten FH, Hoes AW. Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects? Eur J Heart Fail. 2012;14:348–50.PubMedCrossRef
75.
Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, Parra S, Bond RA. Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma model. Pulm Pharmacol Ther. 2008;21:115–24.PubMedCrossRef
76.
Peng H, Bond RA, Knoll BJ. The effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:209–16.PubMedCrossRef
77.
Paolillo S, Pellegrino R, Salvioni E, Contini M, Iorio A, Bovis F, Antonelli A, Torchio R, Gulotta C, Locatelli A, Agostoni P. Role of alveolar β2-adrenergic receptors on lung fluid clearance and exercise ventilation in healthy humans. PLoS One. 2013;8:e61877.PubMedCrossRef
78.
Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38:256–62.PubMedCrossRef
79.
Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, Knoll BJ, Dickey BF, Bond RA. β2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA. 2009;106:2435–40.PubMedCrossRef
80.
Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O’Connor BJ, Page C, Bond RA. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21:134–41.PubMedCrossRef
81.
82.
Page C. Paradoxical pharmacology: turning our pharmacological model upside down. Trends Pharmacol Sci. 2011;32:197–200.PubMedCrossRef
83.
Dickey BF, Walker JKL, Hanania NA, Bond RA. β-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010;10:254–9.PubMedCrossRef
84.
Penn RB. Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:149–69.PubMedCrossRef
85.
Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med. 2013;187:1308–14.PubMedCrossRef
86.
Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med. 2003;97:1014–20.PubMedCrossRef
87.
Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract. 2006;60:415–21.PubMedCrossRef
88.
Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis. 1992;145:301–10.PubMedCrossRef
89.
van den Berge M, Vonk JM, Gosman M, Lapperre TS, Snoeck-Stroband JB, Sterk PJ, Kunz LI, Hiemstra PS, Timens W, Ten Hacken NH, Kerstjens HA, Postma DS. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012;40:1098–105.PubMedCrossRef
90.
Irvin CG. Neutrophils, airway hyperresponsiveness and COPD: true, true and related? Eur Respir J. 2012;40:1067–9.PubMedCrossRef
91.
Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med. 2001;164:109–16.PubMedCrossRef
92.
Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906–13.PubMedCrossRef
93.
Cohn L. Mucus in chronic airway diseases: sorting out the sticky details. J Clin Invest. 2006;116:306–8.PubMedCrossRef
94.
Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD. Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J. 2004;148:915–20.PubMedCrossRef
Metadata
Title
β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives
Authors
Maria Gabriella Matera
Luigino Calzetta
Mario Cazzola
Publication date
01-10-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0120-5

Other articles of this Issue 15/2013

Drugs 15/2013 Go to the issue

Adis Drug Evaluation

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

Review Article

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

Editorial

Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?

Adis Drug Evaluation

Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection

Systematic Review

A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis

Therapy in Practice

Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations